Where does OUR NEW Medical Technologies rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), OUR NEW Medical Technologies ranks #32,786 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does OUR NEW Medical Technologies hold?

OUR NEW Medical Technologies holds 8 US utility patents granted between 2018 and 2022, spanning 7 technology areas.

What is OUR NEW Medical Technologies's Innovation Score?

OUR NEW Medical Technologies has an Innovation Score of 28.2 out of 100 (27th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does OUR NEW Medical Technologies focus on?

OUR NEW Medical Technologies's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 8 patents, ranking #457 of 1,943 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is OUR NEW Medical Technologies's patent grant rate increasing or decreasing?

OUR NEW Medical Technologies's recent grant velocity is +600% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for OUR NEW Medical Technologies's patents?

OUR NEW Medical Technologies's patents average 14.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the OUR NEW Medical Technologies patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

OUR NEW Medical Technologies

USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, recorded in grant years 2018–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, OUR ranks #32,786 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 7 technology areas.

#32,786
of 49,997 US assignees by volume: 27th percentile
by Innovation Score (28.2/100): 14.4
avg claims per patent: +600%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32786 · Foreign Corporation #32,786 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,786/49,997
PHOTO-FINISH Oakmoore Pty
CPC-NARROW A61N · 7 areas
INNOV-THIN 28.2/100
CLAIMS-RICH 14.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +600% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Oakmoore Pty Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How OUR’s 28.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (27%) Velocity 2.7 pts (10%) Breadth 9.4 pts (33%) Claim depth 8.6 pts (30%)

Qualcomm Incorporated · highest

85
OUR NEW Medical · this assignee

28
3D Lighting… · lowest

7

What this shows OUR's Innovation Score is 28.2/100 (27th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for OUR?

Each dot is one of OUR’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). OUR’s own 14.4 claims/patent is at or below the 14.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

OUR vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where OUR's grants concentrate

OUR NEW Medical Technologies is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2020 (4 grants) versus a trough of 1 in 2018. By volume, OUR sits between Orise Technology Co., Ltd. and Octet Medical, Inc..

OUR's three-year grant acceleration

OUR NEW Medical Technologies shows 2 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Orise Technology

8
Osaka Sealing Pri…

8
Osnexus

8
Ostrich Pharma KK

8
OVR Tech

8
Oxford Brookes Un…

8
Oakmoore Pty

8
Octet Medical

8
OUR NEW Medical ◀

8

What this shows OUR holds 8 patents at rank #32,727, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near OUR

By rank, the assignees closest to #32,727 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in OUR's primary technology class.

OUR's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 27th percentile higher than 27% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

OUR NEW Medical Technologies patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	12.5%
2020	4	50.0%
2021	1	12.5%
2022	2	25.0%

Which technologies does OUR NEW Medical Technologies patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 8

G21K - Techniques FOR Handling Particles OR Ionising Radiation NOT Otherwise Provided FOR; Irradiation DEVICES; Gamma RAY OR X-ray Microscopes 2

A61B - DIAGNOSIS; SURGERY; Identification 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

A61G - Transport, Personal Conveyances, OR Accommodation Specially Adapted FOR Patients OR Disabled Persons ; Operating Tables OR CHAIRS; Chairs FOR DENTISTRY; Funeral Devices 1

G21F - Protection Against X-radiation, Gamma Radiation, Corpuscular Radiation OR Particle BOMBARDMENT; Treating Radioactively Contaminated MATERIAL; Decontamination Arrangements Therefor 1

G05B - Control OR Regulating Systems IN GENERAL; Functional Elements OF Such SYSTEMS; Monitoring OR Testing Arrangements FOR Such Systems OR Elements 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

OUR NEW Medical Technologies's patent record in context - here's where to go next.

OUR NEW Medical Technologies's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #32,786 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare OUR NEW Medical Technologies against Orise Technology Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.